|
Year
|
Dietary Supplement
|
FDA Action
|
|
1999
|
Asian Remedy for Menstrual Cramps—Koo Sar
|
Centers for Diseaase Control and Prevention report attributed lead poisoning case to product (posted on FDA website)
|
|
1999
|
Gamma Butyrolactone (GBL)
|
FDA warned consumers not to consume
FDA requested manufacturers to voluntarily recall products (at least one manufacturer agreed to recall)
|
|
1999
|
GBL, Gamma Hydroxybutyric Acid (GHB) and 1,4 Gutanediol (BD)
|
FDA notified HCPs and continues to warn public that these substances are unapproved new drugs that may cause harm
FDA conducted seizures of product
|
|
1999
|
GBL-Related Products
|
FDA warned the public that these are unapproved new drugs that may cause harm
FDA conducted seizures of product
|
|
1998
|
“Sleeping Buddha”
|
FDA warned consumers not to use product because it contains an unlabeled prescription drug ingredient
|
|
1998
|
5-hydroxy-L-tryptophan
|
FDA noted the presence of impurities in some products
|
|
1998
|
Cholestin
|
FDA determined product was an unapproved drug (later upheld by court rulinga)
|
|
1997
|
Chomper
|
FDA warned consumers not to consume product
|
|
1997
|
Ephedrine Dietary Supplements
|
FDA proposed limits to epedrine alkaloids allowed in products. Proposes adding warnings and information in labeling and marketing
|
|
1997
|
Gamma Hydroxybutyric Acid (GHB)
|
FDA reissued warning against use of substance because it is an unapproved and potentially dangerous new drug
FDA and Department of Justice took enforcement actions (restrict importation, embargoes, etc.)
|
|
1997
|
“Herbal Fen-Phen”
|
FDA warned consumers that product is an unapproved and potentially dangerous new drug
FDA took action to remove product from the market
|
|
1997
|
Infant Formula (homemade)
|
FDA informed pediatricians about safety concerns with use
|
|
1997
|
“Plantain” Containing Dietary Supplements
|
FDA warned consumers not to consume dietary supplement products containing plantain because of possible digitalis contamination
FDA worked with manufacturers to identify and recall possibly contaminated products
|
|
1996
|
Street Drugs Containing Botanical Ephedrine
|
FDA warned consumers not to consume products
|
|
1992
|
Chaparral
|
FDA warned consumers to stop use immediately
|
|
a The most recent court ruling held that cholestin was a drug and would be subject to regulation by FDA; however, the case is being appealed (Pharmanex v. Shalala, No. 2:97CV262k, 2001 WL 741419 [D. Utah March 30, 2001], appeal docketed, No. 01–4108 [10th Cir. May 31, 2001]).
|